From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Pedro Nascimento de Lima, PhD
Optimizing Immunotherapy for Advanced NSCLC: How to Manage Immune Toxicities
Jacob Sands, MD
Christine Bestvina, MD
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Charles Turck, PharmD, BCPS, BCCCP
Sairah Ahmed, MD
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Ryan Quigley
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Brian Slomovitz, MD
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Neil M. Iyengar, MD
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Komal Jhaveri, MD, FACP
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Hope S. Rugo, MD, FASCO
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
Gloria Coronado, PhD
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Ashley Baker, MSN, PMHNP
Giancarlo Moscol, M.D.
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Matthew Lunning, DO, FACP
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.